T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues by unknown
T  Cell Responses and Virus Evolution:  Loss of HLA 
All-restricted  CTL Epitopes in Epstein-Barr Virus 
Isolates from Highly All-positive  Populations by 
Selective  Mutation of Anchor Residues 
By P. O. de Campos-Lima,*  V. Levitsky,* J. Brooks,* S. P. Lee,* 
L. F. Hu,* A. B. Rickinson,* and M. G. Masucci* 
From the *Microbiology and Tumor Biology Center, Karolinska Institute, 177 71 Stockholm, 
Sweden; and the tCancer Research Campaign Laboratories, De~rtment of Cancer Studies, 
University of Birmingham, 1315 2TJ, Birmingham, United Kingdom 
Summary 
Epstein-Barr virus (EBV) is a B lymphotropic herpesvirus of humans that elicits strong HLA 
class I-restricted cytotoxic T lymphocyte (CTL) responses. An influence of such responses on 
virus evolution was first suggested by our finding that EBV isolates from the highly HLA All- 
positive Papua New Guinea (PNG) population carried a lys-thr mutation at residue 424 of the 
nuclear antigen EBV-encoded nuclear antigen (EBNA4) that destroyed the immunodominant 
target epitope for All-restricted CTL recognition. Here we turn to a much larger population, 
Southern Chinese, where the All aUde is again present in over 50% of the individuals.  Each 
of 23 EBV isolates analyzed  from this population were also mutated in the EBNA4 416-424 
epitope, the mutations sdectively involving one of the two anchor residues in positions 2 (417 
val-leu) or 9 (424 lys-asp, -arg or -thr) that are critical for All-peptide interaction. The majority 
of the Chinese isolates and all 10 PNG isolates also carried mutations affecting positions 1 and 
2 of the next most immunodominant All-restricted epitope, EBNA4 residues 399-408. These 
changes dearly affected antigenidty since All-positive lymphoblastoid cell lines (LCLs) carrying 
these mutant EBV strains were not recognized by All-restricted CTLs raised against the prototype 
B95.8 virus. Furthermore, Chinese donors naturally infected with these mutant viruses did not 
mount detectable All-restricted CTL responses on in vitro stimulation with autologous LCL 
cells carrying either the B95.8 or their endogenous EBV strain.  In two different highly All- 
positive populations, therefore, immune pressure appears to have sdected for resident EBV strains 
lacking immunodominant All-restricted CTL epitopes. 
C 
TLs appear to play an important role in the control of 
virus infections (1, 2). Such virus-induced CTLs recog- 
nize short peptides, typically 8-11 amino acids in length, that 
are derived by proteolytic degradation of viral proteins and 
that are selected for presentation at the surface of infected 
cells by complexing with nascent MHC class I molecules (3). 
Despite the antigenic complexity of most viruses, the CTL 
response to viral infection is in many instances dominated 
by reactivities directed against a limited number ofimmuno- 
dominant peptide epitopes, the identity of these epitopes being 
strongly influenced by the particular MHC class I alleles of 
the host (4,  5). 
The possibility that viruses might escape CTL surveillance 
in vivo through mutations in an immunodominant  CTL epi- 
tope was first formally demonstrated in studies of lympho- 
cyte choriomeningitis virus (LCMV) infection in a T  cell 
receptor transgenic mouse model (6).  Later, an apparently 
similar T cell driven selection of escape mutants was docu- 
mented in man during the course of natural infection with 
HIV (7). Thus, in special circumstances involving highly ge- 
netically unstable viruses, prospective studies on individual 
carriers can reveal viral adaptation to the prevailing CTL re- 
sponse. It remains to be seen, however, what influence the 
CTL system has had over the evolution of those viruses that 
are genetically stable and that have a long history of coexis- 
tence with their host species. 
Here we examine one such agent, EBV, a lymphotropic 
herpesvirus with growth transforming ability, which is wide- 
spread in human populations and which elicits strong CTL 
responses. Studies on healthy virus carriers have shown that 
EBV-specific CTL memory is predominantly HLA class I-re- 
stricted and directed against the limited number of viral pro- 
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lymphobhstoid cell lines (LCLs) 1 (8-10). Using recombinant 
vaccinia viral vectors and synthetic peptides in CTL sensiti- 
zation assays, a number of immunodominant  CTL epitopes 
have now been identified within these EBV products, each 
presented in the context of a specific I-1LA class I molecule 
(9, 11-15).  In particular,  we have shown that the HLA All 
allele,  which mediates unusually strong EBV-specific CTL 
responses in Caucasian donors, focuses reactivity on a small 
number  of epitopes  in  the  EBV-encoded nudear  antigen 
(EBNA)4  (13).  During  the course of the above work we 
identified natural EBV isolates that were not recognized by 
All-restricted effectors; when compared with the B95.8 pro- 
totype strain,  all showed a lys-thr change at position 9 of 
the most immunodominant  CTL epitope, EBNA4 residues 
416-424,  which abrogated binding  of the peptide to All. 
It is interesting to note that these "epitope-loss variants" 
of EBV were all derived from a Papua New Guinea (PNG) 
population in which the All allde itself is unusually preva- 
lent. This raised the possibility that viral strains hcking the 
major All-restricted CTL epitope had enjoyed a selective ad- 
vantage in this particular population due to their failure to 
elicit strong CTL responses. It has to be remembered, how- 
ever, that PNG populations have an unusually long history 
of isolation  and  are probably derived from smaU  founder 
groups; the prevalence of epitope-loss EBV variants may there- 
fore be a coincidence arising from founder effects rather than 
the specific result of T cell-mediated sdection. Furthermore, 
such viruses, though lacking the immunodominant  epitope 
of the B95.8 strain, might neverthdess be capable of inducing 
strong  All-restricted  CTL  responses  via  other  immuno- 
dominant epitopes peculiar to the PNG isolates. To address 
these issues further, we have turned to a much larger popula- 
tion group, Southern Chinese, which also shows a high fre- 
quency of the HLA All nUde and from which individuals 
are more readily available for analysis of both their resident 
EBV isolates and their virus-specific CTL memory 
Materials  and Methods 
EBV Isolates and Cell Lines.  A total of 63 type A EBV isohtes 
of different geographic origin were included in this study. 29 iso- 
lates (9 Caucasian, 5 African, 7 Chinese, and 8 PNG) were derived 
from EBV carrying LCLs established by spontaneous outgrowth 
from lymphocytes of normal EBV seropositive individuals cultured 
in the presence of 0.1/~g/ml cyclosporin A (16). 17 isohtes (6 Cau- 
casian, 9 African, and 2 PNG) were obtained from previously es- 
tablished tumor cell lines derived from EBV carrying Burkitt's lyre- 
photons and 17 isolates (1 African and 16 Chinese) were directly 
sequenced from EBV carrying nasopharyngeal carcinoma biopsies. 
B95.8 EBV transformed LCLs were obtained by infection of lym- 
phocytes from HLA class I typed donors with spent culture super- 
natants of the virus producer B95.8 line (17). All cell lines were 
1 Abbreviations used in this paper: EBNA, EBV-encoded  nuclear antigen; 
LCL, lymphoblastoid cell line; PNG, Papua New Guinea. 
maintained in R.PMI 1640 supplemented with 100 mg/ml strep- 
tomycin 100 IU/ml penicillin and 10% FCS (complete medium). 
DNA Sequencing by  PCR.  Appropriate oligonucleotide primers 
were chosen t]anking the DNA region coding for the 399-408 and 
416-424 EBNA4 epitopes. One of the primers was biotinyhted 
at the 5' end. PCK-amplilied biotinylated material was separated 
by incubation with Dynabeads M280-streptavidin (Dynal, Oslo, 
Norway). The immobilized double stranded DNA was denatured 
with 0.1 M NaOH at room temperature for 6 min. The biotinyhted 
template DNA was annealed at 65~  for 5 min with 5 pmole of 
the sequencing primers 5'ATAATTGTTGAGG~CGY; 5'CTC- 
TGCTCCATGACTTCA3'  in 14 gtl buffer containing 10 mM Tris- 
HC1 (pH 7.5),  100 mM NaC1, 10 mM MgClz, and 0.1 mg/ml 
BSA. After further incubation for 30 min with 50 mM dATP, dCTP, 
dGTP, fhore-dUTP (Buehringer Mannheim, Mannheim, Germany) 
and 3 U T7 DNA polymerase (Pharmacia LKB, Uppsala, Sweden), 
6 mM dithiothreitol,  and 45 mM NaC1 were added. The reactions 
were divided in 4 aliquots, mixed with one of the 4 didenxinucleo- 
tides, and incubated for 5 rain at 37~  After addition of an equal 
volume of deionized formamide containing 5 mg/m/of blue dex- 
tran, the samples were loaded onto a 0.5-ram thick 6% polyacryl- 
amide gel with 7 M urea and run on an A.L.F. DNA sequencer 
(Pharmada LKB). The same protocol was used for sequencing of 
the nonbiotinyhted strands recovered  in the supernates of the NaOH 
denaturation  step after neutralization  with HC1. 
Synthetic Peptides,  Peptides,  synthesized by the MerriEeld solid 
phase method (18), were purchased from Alta Bioscience  (The Uni- 
versity of  Birmingham, School of  Biochemistry, Birmingham, UK). 
The peptides were dissolved in DMSO at the concentration  of 
10-2 M and further diluted in PBS to obtain the indicated con- 
centrations before the cytotoxidty assays. The protein concentra- 
tion of the DMSO stock solutions was determined by a Biuret 
assay (19). 
Generation of CTL Cultures and Clones.  EBV-specitic  CTLs were 
obtained by autologous  B95.8 LCL stimulation  (20) of lympho- 
cytes from 12 EBV seropositive Caucasian donors: BK (I-ILA A2,11 
B7,35), EA (I-ILA A10,11 B35,51), SI (HLA A2,11 B7,27.03), JAC 
(A1,11 B49,55), KS (HLA A2,11 B35,40), SW (All,24 B7,35), 
DT (A2,11 B44,55), CMC (A2,11 B8,44), SG (A3,11 B35,40), MO 
(HLA A3,11 B35,40), PB (HLA A1,11 B22,37), and KK (HLA 
All,28 B14,40) and 3 EBV sempositive  Chinese donors: QYY (HLA 
A2,11 B13.38), DH (HLA A2,11 B27.04,40), and QJZ (HLA All, 
B13,51). After two or three consecutive restimulatinns,  the cul- 
tures were expanded in complete medium supplemented with 10 
U/ml recombinant Ib2 and 30% (vol/vol) culture supernatant from 
the gibbon lymphoma line MLA144 (21). Single cell cloning was 
done by limiting dilution in 96-well phtes in 200 ~tl medium con- 
taining 30% MLA144 culture supernatant, 10 U/ml human recom- 
binant  Ib2,  and 10  s irradiated (3,000 rad) aUogeneic PHA-acti- 
rated PBLs as feeder (20). Growing cultures were transferred into 
48-well plates and were fed twice a week by replacing half of the 
medium. HLA All-restricted EBV-specitic CTL clones were ex- 
panded into 24-plates and restimuhted weekly with irradiated au- 
tologous LCLs in IL-2 containing  medium.  The EBV specificity 
and HLA class I restriction  of the CTL preparations was inves- 
tigated by testing their cytotoxic activity against a panel of EBV 
positive and negative targets including the autologous  LCLs, al- 
logeneic LCLs matched through single HLA class I alleles, at least 
two ceU lines for each allele, PHA activated  blasts, HLA mismatched 
LCLs, and the prototype NK sensitive target  K562. 
Cytotoxicity Assay.  The cytotoxic activity was assayed in stan- 
dard 5-h SlCr release assays (20). The targets were labeled with 
NaSlCrO4 (0.1 I~Ci/106 cells) for 1 h at 37~  The cytotoxicity 
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in triplicate. To test the ability of synthetic EBNA4 peptides to 
sensitize the targets to CTL lysis, 20 tzl of each peptide were added 
to 4  x  103 SlCr-hbeled targets  (in 20/zl complete medium) in 
triplicate wells of 96 V-shaped well plates. The plates were incubated 
for 1 h at 37~  before addition  of CTLs (4  x  llY/weU in 100 
#1). Peptide toxicities were checked in each assay and were always 
<3%. 
Results 
Epitope Sequ~e  in EBV Isolates of ~O'~nt  Ceograph~ 
Regions.  We have previously shown that five epitope regions 
of the B95.8 EBNA4 protein are capable of inducing All- 
restricted CTL responses (13). These regions differ consider- 
ably in immunogenicity and the immunodominant  epitope 
has been defined as the 9-met peptide IVTDFSVIK, EBNA4 
residues 416-424.  CTLs against this epitope, are present as 
the major component in polyclonal effector populations from 
All-positive Caucasian donors; this is illustrated by results 
obtained using CTLs from donor BK (Fig.  1 A) and from 
the derived done BK d.112 (Fig.  1 B) which was representa- 
five of most clones from the polydonal population. The second 
most common All-restricted component, detectable in poly- 
donal preparations from most but not all All positive donors, 
was originally mapped to EBNA4 residues 396-410. We have 
recently identified the cognate peptide in this region as the 
10-mer AVFDRKSDAK, representing EBNA4 residues 399- 
408 (Levitsky, V., unpublished results). Results illustrating 
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Figure  1.  EBNA4 peptides 
416-424 and 399--408  are the cog- 
nate epitopes of HLA All-re- 
stricted EBV-specific  CTLs. HLA 
All positive PHA bhsts (donor 
QJZ) were preincubated for 1 h 
with a 10-7 M concentration of 
the  synthetic peptides EBNA4 
416-424 and 399-408 and then 
tested for lysis by a polyclonal 
CTL culture from donor BK, pre- 
viously shown to contain a pre- 
dominant All-restricted compo- 
nent, and by the CTL clones BK 
c1.112 and BK d.280 derived  from 
the polyclonal  culture by cloning 
in limiting dilution. The percent 
specific  lysis  recorded  at a 10:1 el- 
lector/target ratio is shown. One 
representative r  oat of 
four is shown. 
recognition of the cognate 399-408 epitope are shown in Fig. 
1 A  for the BK polydonal population  and Fig.  1 C  for a 
representative done BK d.280.  Sequencing of EBV isolates 
across the relevant region of the EBNA4 gene could there- 
fore be undertaken with precise knowledge of the positions 
of these two adjacent epitopes. 
To test the generality of our earlier observation on EBV 
isolates from the highly All-positive PNG population, we 
took advantage of the fact that the All allele is also unusually 
prevalent in other South East Asian populations (22, 23). In 
particular,  the Southern  Chinese represent a large popula- 
tion group in which more >50% of the individuals are All- 
positive (23). Furthermore,  a number of Southern Chinese 
donors (several of whom proved to be All-positive) were avail- 
able to us for virus isolation and CTL generation.  Sponta- 
neous LCLs carrying the individual's resident EBV strain were 
established from seven such Chinese donors and the relevant 
region of the EBNA4 gene was then PCR amplified and se- 
quenced; work was also extended to include 16 EBV isolates 
from Chinese nasopharyngeal carcinoma biopsies, an enlarged 
pand of 10 PNG virus isolates and, for comparison, 15 Cau- 
casian  and  15 African isolates. 
Fig. 2 shows the different sequence patterns observed, with 
mutations being identified relative to the B95.8 prototype 
sequence. AU 23 Chinese isolates examined showed changes 
in the immunodominant  416-424 epitope region;  further- 
more, though a number of different mutations were observed, 
these all sdectively involved one or the other of the two an- 
chor positions, amino acids 2 and 9 of the peptide epitope, 
which  are  known  to be important  determinants  for  All 
binding (24). In almost half of the cases the val in position 
2 was substituted by a leu (L2 mutation),  while in the re- 
maining  cases the lys in position 9 was substituted by asp 
or more rarely by arg or thr (N9, Kg, T9 mutations, respec- 
tivdy). In addition, 13 of the 23 Chinese isolates also showed 
mutations that altered positions 1 and 2 of the 399-408 epi- 
tope from ala-val to either ser-len, pro-leu, or ser-phe ($1L2, 
PlL2, and $1F2 mutations, respectively). One isohte showed 
a single substitution of ala in position 1 to pro. In confirma- 
tion of earlier work, most of the PNG isolates possessed the 
T9 mutation in the 416-424 epitope while a single isolate 
in the extended pand carried the R9 mutation; it is interesting 
to note that every one of these PNG isolates also showed the 
ser-leu or ser-pbe mutation in positions 1 and 2 of the 399-408 
epitope. By contrast,  only a minority of Caucasian isolates 
(from Europe and USA) showed any mutation  relative to 
the B95.8 sequence; when present, these exclusively involved 
the immunodominant 416-424 epitope and were either of the 
L2 or N9 type already represented among the Chinese viruses. 
The majority of Caucasian isolates and, interestingly,  all 15 
African isolates tested were identical to the B95.8 sequence 
throughout  this whole region  of EBNA4. 
SensitMty of  Chinese EBV Isolates to All-restricted  1395.8  EBV- 
induced CTLs.  To examine the effect of such mutations on 
immunological recognition, All-restricted CTL dories of the 
kind illustrated in Fig. 1 (i.e., specific for the EBNA4 416-424 
and 399-408 epitopes of the B95.8 virus) were tested on target 
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stricted  EBNA4 epitopes in EBV 
isolates  of  different  geographic 
origin. Nucleotide and amino acid 
changes relative to  the B95.8  se- 
quence  are  indicated.  Shadowed 
bc0r  identify the sequence of the 
EBNA4  399--408 and  416-424 
epitopes. 
LCLs carrying the endogenous EBV strain that had been es- 
tablished from All-positive Chinese or PNG donors by spon- 
taneous in vitro outgrowth. The panel of target LCLs, each 
confirmed by immunoblotting to be expressing the endoge- 
nous virus-encoded EBNA4 protein (not shown), included 
representatives  of each  of the mutations observed  in  the 
EBNA4 416-424  epitope (QYY-LCL,  L2; QJZ-LCL,  Ng; 
LS-I.CL,  R9; DH-LCL, T9); note that these lines also car- 
ried the $1L2, $1F2, or PIL2 double mutation in the EBNA4 
399-408  epitope. 
Fig.  3  shows  representative  results  obtained  with  the 
416-424  epitope specific done BK c1.112 and the 399-408 
epitope-specific done BK d.280 when tested on the above 
LCL panel. There was no significant lysis of  any of  the spon- 
taneous Chinese LCLs by these effectors (solid bars). How- 
ever, when the B95.8 EBNA4 protein was expressed in these 
cells via a recombinant vaccinia virus vector, all four target 
lines became susceptible to All-restricted CTLs (hatched bars); 
infection of these cells with a control vaccinia recombinant 
had no such effect (stripped bars). This strongly suggested that 
lack of recognition of the spontaneous LCLs reflected an al- 
tered antigenicity of the resident virus strain rather than some 
subtle polymorphism of the All restriction element between 
Caucasian and Chinese  donors. 
Further analysis of this altered antigenicity concentrated 
on those mutations observed  of  the immunodominant 416-424 
epitope on CTL recognition. Peptide sensitization assays were 
carried out to compare the four different epitope variants with 
the cognate B95.8 sequence.  Fig. 4 shows a typical set of  results 
obtained in assays testing the 416-424-specific CTL clone BK 
c1.112 on QYY, QJZ, L5, and DH spontaneous LCL targets 
either alone or after preincubation  with 10-7 M concentra- 
tions of the relevant synthetic peptides. There was again no 
recognition of the LCLs alone but addition of the B95.8 epi- 
tope peptide mediated strong target cell lysis. Interestingly, 
synthetic peptides corresponding  to the N9 and T9 muta- 
tions were not able to sensitize the target cells whereas those 
corresponding to the L2 and 1~9 mutations were recognized 
as e~ciently as the cognate B95.8 epitope sequence. Sensiti- 
zation with the L2- and Rg-mutated peptides was observed 
with all four All-positive LCLs tested, including those where 
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Fig'arc  3.  Lysis  of HLA All positive LCLs carrying Chinese EBV iso- 
htes by B95.8 EBNA4-spedtic CTLs. Spontaneous LCLs from All-positive 
Chinese donors carrying EBNA4 mutated EBV strains were tested for sen- 
sitivity to lysis by CTL clones specific for the B95.8 EBNA4 epitopes 
416-424 (BK d.112) and 399-408  (BK d.280). The targets were either 
untreated ￿9  or had been infected for 6 h at a multiplicity of infection 
of 10:1 with  a control recombinant vaccinia virus  ~  or with a vac- 
cinia recombinant  expressing the B95.8 EBNA4 gene ￿9  We have previ- 
ously shown that cells  infected under these conditions expressed high levels 
of the gene encoded by the vaccinia recombinant  (8). The percent specific 
lysis recorded at a 10:1 effector/target  ratio is shown. One representative 
experiment  out of four is shown. 
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Figure  4.  CTLrecognitionofmutatedEBNA4416-424peptides.  Spon- 
taneous LCLs  from All-posit/ve  Chinese donors carrying EBNA4 mu- 
tated EBV strains  were  tested  for l~is by the B95.8 EBNA4  416-424 specific 
CTL clone  BK d.112 either  untreated or after  preincubation  with 10  -7 M 
of  synthetic  peptides  con~ponding to the B95.8 416-424  epitope  sequence 
or peptides representing  the L2, R9, N9, and T9 mutations. The percent 
specific  lysis recorded  at a 10:1 effector/target  ratio is shown. One repre- 
sentative experiment out  of three is  shown. ￿9  Untreated; m  E4 
416-424; ~1 L2; E! R9; [] N9; [] T9. 
the endogenous virus contained the same mutation. This sug- 
gested that, even when the mutation in the resident virus 
had not destroyed the antigenicity of the EBNA4 epitope, 
presentation of the mutated peptide was in some way impaired. 
Comparison of  All-positive Caucasian and Chinese Donors to 
Autologous LCL Stimulation.  In a first set of experiments, 
HLA All positive Caucasian and Chinese donors were com- 
pared for their ability to generate All-resu'icted EBV-specific 
CTLs after stimulation with autologous LCL cells transformed 
by the reference Caucasian EBV isolate B95.8. Several inde- 
pendent CTL activations were carried out from each donor 
and in each case the allde-spediic component reactivities within 
the overall response were analyzed by testing on the autolo- 
gous LCL and on a panel of B95.8 transformed allogeneic 
LCLs either matched with the donor through a single HLA 
class I allele or completdy HLA class I mismatched. Of 12 
Caucasian donors tested, 10 yidded CTL preparations that 
showed clear HLA class I-restricted EBV-specific memory 
responses with lysis of mismatched LCLs and EBV negative 
targets always below 20% of the autologous LCL lysis. Two 
other Caucasians (KK and PB) failed to mount a detectable 
EBV specific CTL response. As illustrated by representative 
results obtained with 4 donors (BK, SI, EA, JAC; Hg. 5), 
an All-restricted CTL component was present in all 10 cases 
where an EBV-spedfic response was  obtained.  When the 
strength of each individual aUele-specific reactivity is com- 
pared with the level of autologous LCL lysis, it is dear that 
the All-restricted component is in each case the dominant 
reactivity. By contrast, All-restricted reactivities were either 
not detectable above background (i.e., above the lysis of  HLA- 
mismatched LCL targets) or represented only a minor com- 
ponent within CTL preparations from the three All-positive 
Chinese donors tested. These individuals yielded an HLA class 
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Figure 5.  Response  of HLA All positive  Caucasian and Chinese donors to autologous  B95.8 transformed  LCLs. Lymphocytes  from the HLA All 
positive Caucasian donors BK, SI, EA, and JAC and All-positive  Chinese donors QYY, QJZ, and DH were stimulated with autologous  B95.8 virus 
transformed  LCLs. Polyclonal  CTL cultures  obtained  after  three  consecutive  restimulations  were  tested  for lysis  against a panel  ofB95.8  virus transformed 
LCLs including the autologous LCL and ailogeneic  LCLs either matched through a single HLA class I allele  or completely  mismatched. At least two 
single matched LCLs for each allele  and two mismatched LCLs (-) were included  in the panel. The mean percent specific  lysis at 10:1 effector/target 
ratio in 10-20 tests performed  with CTLs from 3-10 independent stimulations for each donor is shown. 
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which appeared to be predominantly restricted through the 
B51 allde in donor QJZ and through the A2 allele in donor 
QYY, but which for the other donor, DH, showed no one 
dominant reactivity. 
We then compared the CTL responses of these Chinese 
donors to in vitro stimulation with their B95.8 LCL to that 
induced by the spontaneous LCL carrying their endogenous 
EBV strain. For all three individuals, there was no significant 
difference in the pattern of cytotoxicity observed; in partic- 
ular the spontaneous LCL never induced an obvious All- 
restricted response. Representative results from donors QJZ 
and QYY are shown in Fig. 6; CTL component restricted 
through the B51 (donor QJZ) and A2 (donor QYY) alleles 
appeared to dominate the response to both spontaneous and 
B95.8 transformed LCLs. Most notably, stimulation with the 
spontaneous LCL failed to induce All-restricted CTL com- 
ponents specifically directed against All-matched LCLs car- 
rying Chinese or PNG virus isolates. Thus, in the case of 
donor QJZ shown in Fig. 6, lysis of the QXL spontaneous 
LCL (an All-matched line carrying the same N9 mutation 
in the 416-424 epitope as the CTL donor) was only slightly 
above background. Finally, we tested such spontaneous LCL- 
induced CTL preparations for their ability to recognize syn- 
thetic peptides rt~resenting the mutated version of the 416-424 
and 399-408 epitopes known to be present in the donor's 
endogenous virus strain;  no epitope specific lysis was ever 
observed (data not shown). 
Discussion 
The existence of EBV-rdated B lymphotropic herpesviruses 
in many old world primate species clearly indicates that these 
agents have coevolved with their host species over millions 
of years. Only in special circumstances, therefore, might one 
be able to discern a specific  influence of host immune responses 
upon the evolution of such genetically stable agents. Our ob- 
servation that all six EBV isolates studied from a highly HLA 
All positive PNG population carried a single point muta- 
tion affecting the mdgenidty of the major All-restricted CTL 
epitope (25) was possibly one such example. To examine this 
possibility more carefully and to assess the generality of our 
initial findings we focused upon EBV isolates from a second 
much larger population group, Southern Chinese, in which 
the All allele is highly prevalent. 
Having identified the two most immunodominant pep- 
tide epitopes for All-restricted responses in Caucasians as 
EBNA4 416-424 and EBNA4 399-408 (13, Fig.  1), we set 
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Figure 6.  Cytotoxic  activity of polyclonal CTL preparations obtained by in vitro stimulation of PBLs from the Chinese donors  QJZ and QYY 
with autologous LCLs carrying the B95.8 virus or the endogenous EBV strain. The percent specific lysis at 10:1 effector/target  ratio is shown. One 
representative experiment out of three is shown. 
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lates  from Southern China and,  as a reference, from addi- 
tional PNG, African, and Caucasian isolates. All 33 Chinese 
and PNG isolates sequenced carried mutations within 416-424 
epitope that selectively involved one or the other of the two 
anchor residues in positions 2 and 9.  Moreover, about half 
of the Chinese isolates and all the PNG isolates showed addi- 
tional mutations in the 399-408  epitope,  again selectively 
affecting both residue  1 and anchor residue 2. 
An important feature of these results is the multiplicity 
of  variants seen amongst Chinese viruses. Thus, we identified 
four independent mutations (L2, R9, T9, and N9) affecting 
the 416-424  epitope in this group of isolates,  whereas iso- 
lates from PNG were more homogeneous (all but one were 
T9). The multiplicity of Chinese strains is further stressed 
by the fact that both the L2 group and the N9 group of iso- 
lates can be further divided into subgroups that either did 
or did not contain mutations in the second epitope. The sep- 
arate origin of these subgroups is confirmed by additional 
sequence data which consistently revealed the presence of two 
additional coding mutations (at residues 380 ser-ala and 461 
gin-his) in all viruses with mutations in the second epitope 
(not shown). In contrast, viruses lacking changes in the second 
epitope were identical to B95.8 over the whole region except 
for the single mutation in the first epitope. This reempha- 
sizes the selective nature of the mutations observed, and is 
consistent with the view that CTL responses directed against 
the immunodominant 416-424 epitope, which was regularly 
mutated in the Chinese isolates, exert the strongest selective 
pressure. 
A common feature of the mutations described in this work 
is that, like the original mutation found in PNG isolates (25), 
they all abrogated recognition by CTLs raised against the 
B95.8 epitope. Thus, All positive spontaneous I,  CLs carrying 
the L2, R9, N9, or T9 mutations were not lysed by B95.8- 
induced CTL dones (Figs. 3 and 4). We would have predicted 
this result on structural ground in the case of the N9 and 
T9 mutations since substitution of the lys anchor residue at 
position 9 by asn or thr is likely to abrogate binding to the 
All groove; as indeed has been shown to be the case for the 
T9 mutant peptide (25).  However, the val-leu substitution 
at position 2 and the lys-arg substitution at position 9 repre- 
sent more conservative changes that are unlikely to impair 
binding. Indeed, synthetic peptides representing the L2 and 
R9 mutant sequences (but not T9 and N9) were able to sen- 
sitize target cells to lysis by CTLs raised against the cognate 
B95.8 epitope sequence (Fig.  4). The L2 and R9 mutations 
identified in Chinese isolates,  therefore, do not abrogate the 
antigenicity of the peptide epitope per se; the cells carrying 
these isolates  nevertheless seem unable to present this epi- 
tope from the endogenously expressed EBNA4 protein. The 
mechanism of this defect is currently under investigation. 
Another important goal of the present study was to assess 
whether such "All epitope-loss" EBV variants did indeed in- 
duce weaker All-restricted CTL responses in their infected 
hosts. We initially observed that three HLA All positive Chi- 
nese donors failed to mount an All-restricted CTL response 
when challenged with autologous B95.8 virus transformed 
B cells, even though EBV-specific responses restricted via other 
alleles were detected (Fig. 5). Furthermore, in vitro stimula- 
tion of these donors' T cells with autologous cells carrying 
the resident EBV isolate still failed to uncover an All-restricted 
component within the CTL memory (Fig. 6). Although the 
number of Chinese donors studied is small, the contrast with 
All-positive Caucasian donors is already very striking since 
All is the preferred restriction element of EBV-specific  re- 
sponses  in  the latter group. 
Two coincidental features of the HLA All allde were key 
factors in the planning of the present study. One was its proven 
capacity to mediate immunodominant CTL responses to EBV 
(26, 27);  the other was the marked variation that exists  in 
All frequency between different human populations. Fig. 7 
1303  de Campos-Lima  et al. 
F~,ure 7.  HLA All antigen  fie- 
quency  in different  ethnic groups. 
Data of  I-ILA  All antigen  fiequency 
in ditferent  human  populations  were 
collected from references  22,  23, 
28-30. Antigen  frequency  was cal- 
culated  from  gene  frequency  data  by 
the formula: AF  ~  1-(GF-1)L 
The figures  include  both the HLA 
All.01 and All.02 subtypes.  Large 
bold numbers  represent  the average 
antigen frequency  in the indicated 
area/ethnic group. illustrates the degree of this variation on a world map, em- 
phasizing the remarkably high allele frequencies which are 
seen in various South East Asian populations. We would also 
stress that these comparisons are unlikely to be greatly affected 
by polymorphism within the All allele family itself. Thus 
of the three known subtypes of All, the only one as yet found 
in Caucasian  populations  (All.02)  is also by far the most 
common subtype present in South East Asia. We therefore 
view as very significant the fact that two different South East 
Asian populations both consistently yielded EBV strains with 
mutations selectively affecting critical residues in All-restricted 
epitope regions. Such mutations were never seen in African 
populations, where All is virtually absent, and occurred in 
only a small fraction of isolates from Caucasian populations 
where the All frequency is roughly 10%. Our studies indi- 
cate that these South East Asian viruses were indeed epitope- 
loss mutants  since they were neither recognized by B95.8- 
induced  All-restricted  CTLs  nor  capable  of  themselves 
eliciting All-restricted responses. We infer that All epitope 
loss had conferred a selective advantage to EBV isolates in 
these particular  host communities. 
The mechanism by which such CTL-mediated selection 
occurs remains to be determined. One interesting possibility 
is that CTL responses may be able to influence the type of 
viral strain which becomes established in the B cell reservoir 
of an individual. Thus, in certain cases, a particularly strong 
primary CTL response, perhaps dominated by reactivity to 
an immunodominant HLA class I-EBV peptide complex, may 
be capable of eliminating virus-infected cells from the body 
early in the infection before virus persistence is established 
in the B cell reservoir; dearly viral strains lacking the rele- 
vant target peptide would have a greater chance of successful 
transmission to such individuals. Another possibility is that 
CTL responses exert their influence during the life-long per- 
sistent infection by controlling the size of the virus-infected 
B cell pool, and thereby the size of the reservoir from which 
transmissible  infectious virus is ultimately derived. If this were 
the case, CTL epitope loss mutants would have a greater chance 
of being reactivated as infectious virus in the oropharynx, 
and hence a greater chance of being transmitted within the 
community. 
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